Protein kinase CK2: a potential therapeutic target for diverse human diseases
CK2 is a constitutively active Ser/Thr protein kinase, which phosphorylates hundreds of
substrates, controls several signaling pathways, and is implicated in a plethora of human …
substrates, controls several signaling pathways, and is implicated in a plethora of human …
Polymeric nanoparticles for targeted drug delivery system for cancer therapy
F Masood - Materials Science and Engineering: C, 2016 - Elsevier
A targeted delivery system based on the polymeric nanoparticles as a drug carrier
represents a marvelous avenue for cancer therapy. The pivotal characteristics of this system …
represents a marvelous avenue for cancer therapy. The pivotal characteristics of this system …
[HTML][HTML] The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
HJ Chon, KJ Bae, Y Lee, J Kim - Frontiers in pharmacology, 2015 - frontiersin.org
The casein kinase 2 (CK2) protein kinase is a pro-survival kinase and therapeutic target in
treatment of various human cancers. CK2 overexpression has been demonstrated in …
treatment of various human cancers. CK2 overexpression has been demonstrated in …
Current concepts and novel targets for antiplatelet therapy
M Gawaz, T Geisler, O Borst - Nature Reviews Cardiology, 2023 - nature.com
Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …
Protein kinase CK2–diverse roles in cancer cell biology and therapeutic promise
JH Trembley, BT Kren, M Afzal, GA Scaria… - Molecular and cellular …, 2023 - Springer
The association of protein kinase CK2 (formerly casein kinase II or 2) with cell growth and
proliferation in cells was apparent at early stages of its investigation. A cancer-specific role …
proliferation in cells was apparent at early stages of its investigation. A cancer-specific role …
Dysregulation of RNA polymerase I transcription during disease
Transcription of the ribosomal RNA genes by the dedicated RNA polymerase I enzyme and
subsequent processing of the ribosomal RNA are fundamental control steps in the synthesis …
subsequent processing of the ribosomal RNA are fundamental control steps in the synthesis …
Enriching screening libraries with bioactive fragment space
N Zhang, H Zhao - Bioorganic & Medicinal Chemistry Letters, 2016 - Elsevier
By deconvoluting 238,073 bioactive molecules in the ChEMBL library into extended Murcko
ring systems, we identified a set of 2245 ring systems present in at least 10 molecules …
ring systems, we identified a set of 2245 ring systems present in at least 10 molecules …
[HTML][HTML] Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones
G Carrà, C Panuzzo, D Torti, G Parvis, S Crivellaro… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Abstract Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder with either
indolent or aggressive clinical course. Current treatment regiments have significantly …
indolent or aggressive clinical course. Current treatment regiments have significantly …
Therapeutic targeting of CK2 in acute and chronic leukemias
F Buontempo, JA McCubrey, E Orsini, M Ruzzene… - Leukemia, 2018 - nature.com
CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is
considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy …
considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy …
Long noncoding RNA HIKER regulates erythropoiesis in Monge's disease via CSNK2B
Excessive erythrocytosis (EE) is a major hallmark of patients suffering from chronic mountain
sickness (CMS, also known as Monge's disease) and is responsible for major morbidity and …
sickness (CMS, also known as Monge's disease) and is responsible for major morbidity and …